Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01493687 · ClinicalTrials.gov registry record · Phase 3
Phase 3 Papulopustular Rosacea Study
A Phase 3 study, sponsored by Galderma R&D.
- Completed
- Registry status
- Phase 3
- Development phase
- 683
- Enrollment target
NCT01493687 is a Phase 3 study that has completed, run by Galderma R&D. The registered enrollment target is 683 participants.
The verdict
NCT01493687, a Phase 3 study, has completed, sponsored by Galderma R&D.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 683 participants
- Enrollment target
Study Summary
The purpose of this study is to demonstrate that CD5024 1% cream is more effective than its vehicle when applied once daily, at bed time, during a 12 week period in subjects with Papulopustular Rosacea (PPR) and continues to be safe up to 12 months.
Interventions
- DRUG CD5024
- DRUG Azelaic acid 15% Gel
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 683 participants |
| Start Date | 2011-12 |
| Est. Completion | 2013-08 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01493687
The ClinicalTrials.gov registry entry for NCT01493687 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 683 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Galderma R&D, which has 158 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which CD5024 is the first listed.
NCT01493687 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01493687 about?
NCT01493687 is a clinical study titled "Phase 3 Papulopustular Rosacea Study". The purpose of this study is to demonstrate that CD5024 1% cream is more effective than its vehicle when applied once daily, at bed time, during a 12 week period in subjects with Papulopustular Rosacea (PPR) and continues to be safe up to 12 months.
What is the current status of trial NCT01493687?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 683 participants. The study started on 2011-12. Estimated completion is 2013-08.
What interventions are being tested in trial NCT01493687?
The interventions under investigation include: CD5024 (DRUG), Azelaic acid 15% Gel (DRUG).
Who is sponsoring clinical trial NCT01493687?
This trial is sponsored by Galderma R&D, which has 158 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.